HomeCompareABDDF vs ABBV

ABDDF vs ABBV: Dividend Comparison 2026

ABDDF yields 0.73% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABDDF wins by $106.2K in total portfolio value· pulled ahead in Year 9
10 years
ABDDF
ABDDF
● Live price
0.73%
Share price
$16.80
Annual div
$0.12
5Y div CAGR
79.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$208.5K
Annual income
$116,645.77
Full ABDDF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — ABDDF vs ABBV

📍 ABDDF pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodABDDFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ABDDF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ABDDF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ABDDF
Annual income on $10K today (after 15% tax)
$62.18/yr
After 10yr DRIP, annual income (after tax)
$99,148.90/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABDDF beats the other by $78,092.90/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ABDDF + ABBV for your $10,000?

ABDDF: 50%ABBV: 50%
100% ABBV50/50100% ABDDF
Portfolio after 10yr
$155.4K
Annual income
$70,708.77/yr
Blended yield
45.50%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

ABDDF
No analyst data
Altman Z
5.8
Piotroski
7/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ABDDF buys
0
ABBV buys
0
No recent congressional trades found for ABDDF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricABDDFABBV
Forward yield0.73%3.06%
Annual dividend / share$0.12$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR79.2%40.6%
Portfolio after 10y$208.5K$102.3K
Annual income after 10y$116,645.77$24,771.77
Total dividends collected$180.3K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: ABDDF vs ABBV ($10,000, DRIP)

YearABDDF PortfolioABDDF Income/yrABBV PortfolioABBV Income/yrGap
1$10,831$131.09$11,550$430.00$719.00ABBV
2$11,827$237.80$13,472$627.96$1.6KABBV
3$13,090$434.88$15,906$926.08$2.8KABBV
4$14,812$806.08$19,071$1,382.55$4.3KABBV
5$17,377$1,527.63$23,302$2,095.81$5.9KABBV
6$21,594$3,001.36$29,150$3,237.93$7.6KABBV
7$29,353$6,246.65$37,536$5,121.41$8.2KABBV
8$45,628$14,220.28$50,079$8,338.38$4.5KABBV
9← crossover$85,842$37,020.52$69,753$14,065.80+$16.1KABDDF
10$208,497$116,645.77$102,337$24,771.77+$106.2KABDDF

ABDDF vs ABBV: Complete Analysis 2026

ABDDFStock

AB Dynamics plc, through its subsidiaries, engages in the design, development, manufacture, and supply of vehicle test and development systems, and verification products and services for advanced driver assistance systems (ADAS), autonomous vehicle technology, and vehicle dynamics in the United Kingdom, Germany, the United States of America, China, Japan, Singapore, and internationally. The company offers advanced vehicle testing solutions from physical proving ground automation to large scale virtual testing in simulation; rFpro, a simulation environment for the automotive and motorsport industries; and full-scale track testing services, including ADAS and vehicle dynamics tests, along with applied research, human factors, and simulation. It also provides automotive testing services comprising evaluations of ADAS systems, infotainment, connectivity, electric vehicle performance and charging, and other associated functions; and retrofit solutions that enable the automation of conventional vehicle fleets rapidly and cost-effectively. In addition, the company creates and deploys a range of Driver-in-the-Loop (DIL) simulators for all types of vehicles, driving scenarios, experiments, and product development aims; supplies end-to-end simulation solutions, such as hardware, software, application consultancy, training, and aftermarket support; and advanced vehicle testing solutions from physical proving ground automation to virtual testing in simulation. Its products are used to evaluate vehicle dynamics, noise, vibration, and harshness and autonomy for a range of applications comprise conventional vehicles, motorsport, and automated/autonomous vehicles. The company was founded in 1982 and is headquartered in Bradford-on-Avon, the United Kingdom.

Full ABDDF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this ABDDF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ABDDF vs SCHDABDDF vs JEPIABDDF vs OABDDF vs KOABDDF vs MAINABDDF vs JNJABDDF vs MRKABDDF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.